Business
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution
HEMANGEOL® is the only FDA-approved treatment for infantile hemangiomaHEMANGEOL will be commercialized by Eton beginning May 1stHEMANGEOL will be distributed through the company’s Eton Cares™ patient support program, which includes a $0 co-pay initiative, to broaden patient access. DEER PARK, Ill., March 02, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rar
About this update from Eton Pharmaceuticals, Inc.
[{"type":"image","alt":"Eton Pharmaceuticals","displaySize":"","headline":null,"caption":"Eton Pharmaceuticals","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":86,"url":"https://media.zenfs.com/en/globenewswire.com/28f8553e49220b3671789b0841a3f340"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/tNWDlhN7QWWIJSsJP_nqbA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/28f8553e49220b3671789b0841a3f340","width":300,"height":86}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"HEMANGEOL® is the only FDA-approved treatment for infantile hemangioma","length":70,"tagName":"p"}]},{"val":[{"type":"text","content":"HEMANGEOL will be commercialized by Eton beginning May 1st","length":58,"tagName":"p"}]},{"val":[{"type":"text","content":"HEMANGEOL will be distributed through the company’s Eton Cares™ patient support program, which includes a $0 co-pay initiative, to broaden patient access.","length":154,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":282,"olType":false},{"type":"text","content":"DEER PARK, Ill., March 02, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced it has in-licensed U.S. commercialization rights to HEMANGEOL® oral solution from Pierre Fabre Medicament Sas (“Pierre Fabre”). HEMANGEOL is an Orphan Drug indicated for the treatment of proliferating infantile hemangioma requiring systemic therapy.","length":494,"tagName":"p"},{"type":"text","content":"“As the only treatment for infantile hemangiomas that require systemic therapy, HEMANGEOL is a critical medication and a strong fit with Eton’s orphan-focused commercial model. We look forward to expanding access to treatment by incorporating our Eton Cares patient support program, which includes our $0 commercial co-pay and best-in-class specialty distribution,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals.","length":416,"tagName":"p"},{"type":"text","content":"“With this acquisition and the recent approval of DESMODA™ (desmopressin acetate), Eton has now achieved its long-held goal of ten commercial products,” Brynjelsen continued. “This major milestone reflects our continued progress toward building the la...